LUX-Lung7 and ARCHER1050 studies established the efficacy and safety of second-generation TKI (afatiyou or dactinib) in patients with untreated EGFR-positive NSCLC (19, 20).The third-generation TKI osimertinib effectively overcome the problem of drug resistance caused by T790M mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.